IntelliCell Opens New Flagship Medical Facility

Jun 04, 2012, 08:30 ET from IntelliCell BioSciences, Inc.

NEW YORK, June 4, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it has opened its new Tissue Processing Laboratory medical facility at 460 Park Avenue, 17th floor, New York, NY, in conjunction with the ReGen Medical, PC medical practice.  As a measure of its commitment to be compliant with the FDA, IntelliCell is engaged with biologics and legal experts to assist the Company with compliance issues related to applicable federal and state regulations. IntelliCell has implemented a new Quality Assurance (QA) unit by employing a new QA director with 10 years of experience in cellular tissue management to assist with IntelliCell's compliance-oriented approach.  IntelliCell is also working with Biologics Consulting Group (BCG) and the Buchanan Ingersoll & Rooney legal team to continue to work on its policies and procedures to be compliant with the FDA.

Dr. Steven Victor, CEO of IntelliCell, stated, "It is an exciting moment for IntelliCell and its affiliate, ReGen Medical, PC, to finally move into its new state-of-the-art facility.  It has taken a year to build out the new space which consists of 2 quad AAAA operating rooms and a new Tissue Processing Laboratory."

About IntelliCell BioSciences

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact:
(212) 843-9337  

SOURCE IntelliCell BioSciences, Inc.